Search

Your search keyword '"Li, Xilei"' showing total 200 results
Start Over Author "Li, Xilei"
200 results on '"Li, Xilei"'

9. Dependent Growth: A Study on the Dilemma and Countermeasures of Social Work Cultivating Community Self-organization

Author

Li, Xilei, Striełkowski, Wadim, Editor-in-Chief, Black, Jessica M., Series Editor, Butterfield, Stephen A., Series Editor, Chang, Chi-Cheng, Series Editor, Cheng, Jiuqing, Series Editor, Dumanig, Francisco Perlas, Series Editor, Al-Mabuk, Radhi, Series Editor, Scheper-Hughes, Nancy, Series Editor, Urban, Mathias, Series Editor, Webb, Stephen, Series Editor, Ali, Ghaffar, editor, Birkök, Mehmet Cüneyt, editor, and Khan, Intakhab Alam, editor

Published
2022
Full Text
View/download PDF

26. Spine‑specific downregulation of LAPTM5 expression promotes the progression and spinal metastasis of estrogen receptor‑positive breast cancer by activating glutamine‑dependent mTOR signaling

Author

Meng, Qingbing, primary, Zhou, Lei, additional, Liang, Haifeng, additional, Hu, Annan, additional, Zhou, Hao, additional, Zhou, Jian, additional, Zhou, Xiaogang, additional, Lin, Hong, additional, Li, Xilei, additional, Jiang, Libo, additional, and Dong, Jian, additional

Published
2022
Full Text
View/download PDF

27. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis

Author

Liang, Haifeng, primary, Chen, Qing, additional, Hu, Zhichao, additional, Zhou, Lei, additional, Meng, Qingbing, additional, Zhang, Taiwei, additional, Wang, Ben, additional, Ge, Yuxiang, additional, Lu, Shunyi, additional, Ding, Wang, additional, Zhou, Xiaogang, additional, Li, Xilei, additional, Lin, Hong, additional, Jiang, Libo, additional, and Dong, Jian, additional

Published
2022
Full Text
View/download PDF

38. Additional file 1 of Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Author

Wang, Zhenqing, Chen, Liang, Ma, Yiqun, Li, Xilei, Hu, Annan, Wang, Huiren, Wang, Wenxing, Li, Xiaomin, Tian, Bo, and Dong, Jian

Abstract

Additional file 1: Fig. S1. Scanning electron microscopy image of as-prepared UCMS. Fig. S2. Purity of IDO peptide AL-9 determined by HPLC. Fig. S3. Mass spectrometric analysis of IDO peptide AL-9. Fig. S4. Fourier transform infrared spectra of as-prepared UCMS, UCMS@Pep, and UCMS@Pep-aPDL1. Fig. S5. (A) The fluorescent emission and (B) intensity value of FITC-labeled aPDL1 solution at different concentrations. Fig. S6. CLSM images of tumor cells treated with the complete culture medium and UCMS@Pep-RB for 4 h. The green fluorescence was emitted by UCMS@Pep-RB under irradiation with a 980 nm laser. Fig. S7. The cumulative release of RB from UCMS@Pep-aPDL1 under pH 7.4 and 5.5 at different time points. Fig. S8. Mean fluorescence intensity (MFI) of CRT expression in vitro (ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, n=3) Fig. S9. MFI of HMGB1 expression in vitro (ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, n=3)). Fig. S10. The blood circulation of UCMS@Pep-aPDL1 in mice after intravenous injection as determined by measuring Fe element at different time intervals (n=3). Fig. S11. Accumulation of UCMS@Pep-aPDL1 labeled by Cy7 in major organs and tumors and the related MFIs (n ≥ 3). Fig. S12. Results of routine blood count in mice treated with PBS and UCMS@Pep-aPDL1 (n ≥ 3). Fig. S13. Weight of tumors in every group. (*P < 0.05, **P < 0.01, ***P < 0.001, n≥3). Fig. S14. Overview of gating strategy for DCs (A) and Gating strategy of DCs (A) and T cells including CD4+ and CD8+ T cells and regular T cells (B). For DCs, briefly, firstly gating FSC-A versus FSC-H for single cells, followed by Live cells based on Zombie UV-negative cells (A, a-b). From viable cells, DCs (CD45+CD11c+) can be determined (A, c-e). Within the CD11c+ DCs, the maturation of DCs (CD80+CD86+) can be determined. For T cells, briefly, viable cells were determined by firstly gating FSC-A versus FSC-H for single cells, followed by lymphocytes based on FSC-A and SSC-A, and lastly CD45+ and Zombie UV-negative cells (B, a-c). From lymphocytes, CD4+ T cells (CD3+CD4+CD8−), CD8+ T cells (CD3+CD4-CD8+) can be determined (B, d-f). Within the CD4+ T cells, regulatory T cells can be determined as CD4+CD25+. Fig. S15. The quantitative results of DCs (A), CD4+ and CD8+ T cells (B,C) and Treg (D) filtration in tumor tissue (*P < 0.05, **P < 0.01, ***P < 0.001, n≥3). Fig. S16. Flow cytometric analyses of DCs, CD4 and CD8 T cells and Treg cells in the spleens of mice immunized using different interventions. Fig. S17. Kyn/Trp ratio in blood serum and tumor tissue. (*P < 0.05, **P < 0.01, ***P < 0.001, n≥3).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results